Helena Danielson at Beactica AB
Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. The research related to UBIMOTIF will be conducted in a group of biochemists/biophysicists, with support from medicinal chemists and computational chemists.
This project will involve development of strategies for targeting complex protein-protein interactions using biophysical approaches. It specifically involves the identification of hits and leads targeting several classes of ubiquitin ligases and deubiquitylating enzymes (DUBs). It will be focused on the adaptation of Beactica’s SPR-based platform for peptide-based lead discovery.
Helena Danielson
Beactica AB
Email Helena Danielson
Beactica's Website
Helena Danielson's website at Uppsala University
